Neutrojen P 50 Supraselective
(Intra-arterial – Basilar route) Aimed at sufficient endogenous dopamine release by revascularized neurons

Neutrojen P 50 Proprietary biologic / Bone Marrow derived mononuclear cells (autologous trial)

1Y: 30D, 3M, 6M, 12M Baseline: diagnostic tests, Gadolinium MRI Brain & Spine, UV exposure, vitamin D synthesis, tests for recognized genetic mutations;

LRRK2, PARK7, PINK1, PRKN, or SNCA and the GBA & UCHL1 genes, MDS-UPDRS, 25 foot walk test (ambulatory subjects), end-point MRI

Revascularization in the substantia nigra; improved dopamine production, improved walking gate, walk-time, UV exposure, vitamin D synthesis log, change in lesion volume (if detected in baseline MRI)

Inclusion criteria: Idiopathic Parkinsonism (PD); M/F (Ag18- 70); Spinal stenosis (Myelopathy) negative, Chronic cerebrospinal venous insufficiency (CCSVI) rule-out via CTV/MRV, If drug-induced, 3-months post discontinuation of Thorazine (chlorpromazine), Haldol (haloperidol), Reglan (metoclopramide), Depacon (valproate) and all dopamine antagonists (as applicable). Patients diagnosed with Vascular and forms of secondary parkinsonism originating from ischemic cerebrovascular disease; arteriosclerotic parkinsonism, vascular pseudo- parkinsonism, and lower body parkinsonism may not be included and will require to follow the Neutrojen S 105 Supraselective protocol (first), recognized genetic mutations may disqualify patients